Puma Biotechnology Announces Publication of Results from Phase II SUMMIT ‘Basket’ Trial Evaluating Neratinib in HER2 and HER3 Mutant Cancers

Published: 1/02/2018
Puma Biotechnology Announces Publication of Results from Phase II SUMMIT ‘Basket’ Trial Evaluating Neratinib in HER2 and HER3 Mutant Cancers
Source: WWW.BUSINESSWIRE.COM

LOS ANGELES--(BUSINESS WIRE)--Puma announced that result from its Phase II SUMMIT ‘Basket’ trial evaluating neratinib in HER2 and HER3 Mutant Cancer were published online in Nature

Read more
Related news
Comment
FACEBOOK